# An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)

> **NCT00430742** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 600 (actual)

## Conditions studied

- Obesity Type 2 Diabetes Mellitus
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Taranabant
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00430742
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-11
- **Target enrollment:** 600 (ACTUAL)
- **Why stopped:** The overall profile does not support development for obesity
- **Last updated:** 2015-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430742, "An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00430742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*